Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 1

Status

Completed 6Active not recruiting 4Recruiting 2

Sponsor Class

OTHER 3NIH 3

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 6

Conditions

Ovarian Neoplasms 13Fallopian Tube Neoplasms 12Colorectal Neoplasms 8Melanoma 6Glioblastoma 5Uterine Cervical Neoplasms 4Gliosarcoma 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Brenner Tumor 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrent Squamous Cell Lung Carcinoma 3Rectal Neoplasms 3Prostatic Neoplasms 3Oligodendroglioma 3Colonic Neoplasms 3Brain Neoplasms 3Uveal Melanoma 2Spinal Cord Neoplasms 2Pancreatic Neoplasms 2Medulloblastoma 2Lung Neoplasms 2Glioma 2Carcinoma, Hepatocellular 2Astrocytoma 2Vulvar Neoplasms 1Virus Diseases 1Vipoma 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Melanoma × Immunoglobulin G × Clear all
NCT01950390 2025-12-11

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
169 enrolled 14 charts
Dermatologic

Melanoma

NCT02519322 2024-04-05

Neoadjuvant and Adjuvant Checkpoint Blockade

M.D. Anderson Cancer Center

Phase 2 Completed
53 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT02112032 2021-05-05

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

University of Pittsburgh

Phase 1 Completed
43 enrolled
Dermatologic

Melanoma

NCT02158520 2020-01-21

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Academic and Community Cancer Research United

Phase 2 Completed
24 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT00387751 2017-11-22

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
14 enrolled 5 charts
Dermatologic

Melanoma

NCT00397982 2017-06-09

Mel47

National Cancer Institute (NCI)

Phase 2 Completed
17 enrolled 12 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡